Answers are grounded in this paper and cite their sources.
Mpox, endemic to Central and West Africa, has recently seen a rise in cases in non-endemic regions, emphasizing the need for specific vaccines. The Mpox virus (MPXV) produces two infectious virions: intracellular mature virions (IMvs) and extracellular enveloped virions (EEvs). IMVs mediate host-to-host transmission, while EEvs facilitate viral dissemination within tissues. This study aimed to develop and evaluate recombinant protein-based vaccine formulations targeting MPXV A29L (IMV), A30L (IMV), and A35R (EEV) proteins to enhance immune responses. Four alum-adjuvanted recombinant protein vaccine formulations containing A29L, A30L and A35R antigens were developed based on the high sequence homology of MPXV with variola and vaccinia viruses. The vaccines were formulated with an alum adjuvant and administered to BALB/c mice. Antigen-specific immune responses were assessed by measuring IgG titers and analyzing cytokine expression profiles to determine the polarization of Th1/Th2 cells. The vaccine formulations induced significant increases in antigen-specific IgG titers in immunized BALB/c mice, with the trivalent A29L+A30L+A35R formulation eliciting the highest overall antigen-specific IgG response. Cytokine expression analysis indicated a predominantly Th2-biased immune response. These findings demonstrate the immunogenicity of A29L, A30L, and A35R proteins when combined with an alum adjuvant and provide an immunogenicity proof-of-concept for their further evaluation as recombinant protein-based MPXV vaccine antigens.
No takes yet. Share an insight, caveat, or question.
Soydam et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: